| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 124 | 2025 | 324 | 30.640 |
Why?
|
| Biomarkers | 65 | 2024 | 1847 | 4.840 |
Why?
|
| Cardiac Surgical Procedures | 32 | 2025 | 492 | 4.050 |
Why?
|
| Renal Replacement Therapy | 16 | 2025 | 36 | 3.590 |
Why?
|
| Sepsis | 10 | 2024 | 351 | 3.570 |
Why?
|
| Creatinine | 32 | 2023 | 296 | 3.020 |
Why?
|
| Critical Illness | 19 | 2025 | 327 | 2.910 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 12 | 2023 | 24 | 2.890 |
Why?
|
| Artificial Intelligence | 8 | 2023 | 356 | 2.460 |
Why?
|
| Renal Insufficiency, Chronic | 12 | 2025 | 236 | 2.280 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 12 | 2023 | 22 | 2.140 |
Why?
|
| Kidney | 18 | 2023 | 1144 | 2.110 |
Why?
|
| Nephrology | 7 | 2025 | 44 | 2.010 |
Why?
|
| Renal Dialysis | 14 | 2024 | 340 | 1.990 |
Why?
|
| Furosemide | 7 | 2023 | 36 | 1.770 |
Why?
|
| Cystatin C | 12 | 2018 | 28 | 1.680 |
Why?
|
| Lipocalins | 13 | 2015 | 34 | 1.570 |
Why?
|
| Humans | 145 | 2025 | 92340 | 1.550 |
Why?
|
| Acute-Phase Proteins | 13 | 2015 | 36 | 1.470 |
Why?
|
| Aftercare | 2 | 2022 | 88 | 1.380 |
Why?
|
| Intensive Care Units | 10 | 2025 | 429 | 1.360 |
Why?
|
| Prospective Studies | 42 | 2023 | 4471 | 1.220 |
Why?
|
| Proto-Oncogene Proteins | 13 | 2015 | 681 | 1.190 |
Why?
|
| Delphi Technique | 3 | 2024 | 105 | 1.120 |
Why?
|
| Postoperative Complications | 15 | 2021 | 2453 | 1.100 |
Why?
|
| Interleukin-18 | 9 | 2016 | 26 | 1.070 |
Why?
|
| Machine Learning | 3 | 2023 | 298 | 1.070 |
Why?
|
| Risk Assessment | 14 | 2023 | 2368 | 1.050 |
Why?
|
| Respiration, Artificial | 7 | 2022 | 379 | 1.050 |
Why?
|
| Chemokines, CC | 3 | 2024 | 37 | 1.030 |
Why?
|
| Glomerular Filtration Rate | 12 | 2020 | 279 | 1.020 |
Why?
|
| Urinalysis | 4 | 2021 | 31 | 1.010 |
Why?
|
| Lipocalin-2 | 17 | 2023 | 37 | 0.980 |
Why?
|
| Precision Medicine | 6 | 2024 | 425 | 0.960 |
Why?
|
| Kidney Function Tests | 8 | 2017 | 117 | 0.940 |
Why?
|
| Risk Factors | 23 | 2022 | 5706 | 0.900 |
Why?
|
| Early Diagnosis | 10 | 2023 | 130 | 0.870 |
Why?
|
| Patient Discharge | 2 | 2024 | 338 | 0.860 |
Why?
|
| Electronic Health Records | 5 | 2025 | 364 | 0.860 |
Why?
|
| Diuretics | 5 | 2018 | 78 | 0.860 |
Why?
|
| Oliguria | 2 | 2024 | 6 | 0.830 |
Why?
|
| Middle Aged | 47 | 2025 | 27043 | 0.780 |
Why?
|
| Aged | 45 | 2025 | 19951 | 0.780 |
Why?
|
| Hospitalization | 7 | 2023 | 925 | 0.780 |
Why?
|
| Kidney Diseases | 4 | 2017 | 322 | 0.780 |
Why?
|
| Male | 61 | 2025 | 43927 | 0.760 |
Why?
|
| Biological Assay | 1 | 2022 | 81 | 0.750 |
Why?
|
| Female | 60 | 2025 | 47893 | 0.710 |
Why?
|
| Dialysis Solutions | 1 | 2020 | 7 | 0.710 |
Why?
|
| Severity of Illness Index | 11 | 2024 | 1920 | 0.700 |
Why?
|
| Heart Failure | 3 | 2020 | 1341 | 0.700 |
Why?
|
| Kidney Failure, Chronic | 3 | 2015 | 415 | 0.650 |
Why?
|
| Prognosis | 18 | 2023 | 3872 | 0.630 |
Why?
|
| Critical Care | 7 | 2025 | 398 | 0.630 |
Why?
|
| Patient Care | 1 | 2020 | 102 | 0.620 |
Why?
|
| Mobile Applications | 1 | 2020 | 76 | 0.620 |
Why?
|
| Kidney Tubules | 3 | 2017 | 92 | 0.620 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 64 | 0.600 |
Why?
|
| ROC Curve | 9 | 2024 | 786 | 0.600 |
Why?
|
| Hemofiltration | 1 | 2018 | 9 | 0.600 |
Why?
|
| Adult | 26 | 2025 | 27538 | 0.570 |
Why?
|
| Albuminuria | 6 | 2016 | 48 | 0.570 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 205 | 0.560 |
Why?
|
| Aged, 80 and over | 21 | 2021 | 6920 | 0.550 |
Why?
|
| Predictive Value of Tests | 13 | 2022 | 1761 | 0.550 |
Why?
|
| Creatine | 1 | 2017 | 26 | 0.540 |
Why?
|
| Area Under Curve | 6 | 2019 | 337 | 0.530 |
Why?
|
| Liver Diseases | 2 | 2015 | 246 | 0.520 |
Why?
|
| Kidney Glomerulus | 1 | 2017 | 122 | 0.510 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 210 | 0.500 |
Why?
|
| Physicians | 1 | 2023 | 693 | 0.500 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 436 | 0.490 |
Why?
|
| Cohort Studies | 18 | 2022 | 2978 | 0.480 |
Why?
|
| Coronary Artery Bypass | 3 | 2019 | 245 | 0.480 |
Why?
|
| Arterial Pressure | 1 | 2015 | 40 | 0.470 |
Why?
|
| Multiple Organ Failure | 3 | 2023 | 55 | 0.470 |
Why?
|
| Acute Lung Injury | 2 | 2009 | 66 | 0.450 |
Why?
|
| Cytokines | 1 | 2018 | 843 | 0.440 |
Why?
|
| Pharmacogenetics | 4 | 2019 | 448 | 0.440 |
Why?
|
| Ventilator-Induced Lung Injury | 2 | 2015 | 32 | 0.440 |
Why?
|
| Retrospective Studies | 11 | 2024 | 9689 | 0.430 |
Why?
|
| Disease Progression | 7 | 2021 | 1505 | 0.420 |
Why?
|
| Patient Care Team | 2 | 2015 | 296 | 0.420 |
Why?
|
| Renal Insufficiency | 2 | 2023 | 98 | 0.410 |
Why?
|
| Time Factors | 12 | 2016 | 5429 | 0.410 |
Why?
|
| Workload | 1 | 2014 | 130 | 0.410 |
Why?
|
| Consensus | 6 | 2024 | 375 | 0.400 |
Why?
|
| Quality Improvement | 4 | 2023 | 474 | 0.400 |
Why?
|
| Anuria | 1 | 2012 | 6 | 0.380 |
Why?
|
| Survivors | 2 | 2024 | 199 | 0.380 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2012 | 13 | 0.380 |
Why?
|
| Proteinuria | 5 | 2021 | 69 | 0.370 |
Why?
|
| Algorithms | 2 | 2018 | 1960 | 0.370 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 1150 | 0.360 |
Why?
|
| Oxygen | 1 | 2015 | 763 | 0.330 |
Why?
|
| Models, Biological | 1 | 2016 | 1786 | 0.320 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 741 | 0.310 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 5 | 2016 | 17 | 0.290 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2019 | 69 | 0.290 |
Why?
|
| Incidence | 5 | 2021 | 1661 | 0.280 |
Why?
|
| Membrane Glycoproteins | 4 | 2015 | 439 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 1072 | 0.280 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 260 | 0.270 |
Why?
|
| Antioxidants | 1 | 2008 | 224 | 0.270 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 148 | 0.260 |
Why?
|
| Child | 9 | 2023 | 7309 | 0.260 |
Why?
|
| Motor Activity | 4 | 2002 | 330 | 0.250 |
Why?
|
| Receptors, Virus | 4 | 2015 | 75 | 0.250 |
Why?
|
| Sensitivity and Specificity | 5 | 2019 | 2009 | 0.250 |
Why?
|
| Models, Statistical | 2 | 2020 | 578 | 0.250 |
Why?
|
| Heart-Assist Devices | 1 | 2014 | 864 | 0.240 |
Why?
|
| Blood Pressure | 1 | 2009 | 907 | 0.240 |
Why?
|
| Complement Inactivating Agents | 1 | 2025 | 6 | 0.240 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 290 | 0.240 |
Why?
|
| Quantitative Trait, Heritable | 3 | 2001 | 124 | 0.240 |
Why?
|
| Hospital Mortality | 3 | 2025 | 444 | 0.230 |
Why?
|
| Crosses, Genetic | 4 | 2002 | 172 | 0.230 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 871 | 0.220 |
Why?
|
| United States | 9 | 2024 | 7348 | 0.220 |
Why?
|
| Blood Urea Nitrogen | 2 | 2016 | 34 | 0.220 |
Why?
|
| Ligands | 2 | 2023 | 457 | 0.220 |
Why?
|
| Fluid Therapy | 2 | 2018 | 53 | 0.220 |
Why?
|
| Hypertension | 1 | 2009 | 763 | 0.210 |
Why?
|
| Chromosome Mapping | 3 | 2002 | 1078 | 0.210 |
Why?
|
| Europe | 1 | 2024 | 328 | 0.210 |
Why?
|
| Comorbidity | 2 | 2018 | 986 | 0.200 |
Why?
|
| Pharmacogenomic Testing | 3 | 2019 | 105 | 0.200 |
Why?
|
| Length of Stay | 3 | 2022 | 790 | 0.200 |
Why?
|
| Costs and Cost Analysis | 1 | 2023 | 154 | 0.190 |
Why?
|
| Patients | 1 | 2023 | 107 | 0.190 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 996 | 0.180 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2018 | 28 | 0.180 |
Why?
|
| Noninvasive Ventilation | 1 | 2022 | 37 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2013 | 95 | 0.180 |
Why?
|
| Chemokine CCL2 | 1 | 2021 | 48 | 0.180 |
Why?
|
| Congresses as Topic | 2 | 2019 | 120 | 0.180 |
Why?
|
| Heart Diseases | 2 | 2015 | 308 | 0.180 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 176 | 0.180 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2025 | 160 | 0.180 |
Why?
|
| Epidermal Growth Factor | 1 | 2021 | 118 | 0.180 |
Why?
|
| Child, Preschool | 7 | 2023 | 3805 | 0.170 |
Why?
|
| Research Design | 1 | 2024 | 600 | 0.170 |
Why?
|
| Treatment Outcome | 6 | 2025 | 8730 | 0.170 |
Why?
|
| Water Supply | 1 | 2020 | 62 | 0.170 |
Why?
|
| Glutathione Transferase | 2 | 2010 | 112 | 0.170 |
Why?
|
| Benchmarking | 1 | 2020 | 80 | 0.170 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 3776 | 0.160 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2019 | 12 | 0.160 |
Why?
|
| Polymorphism, Genetic | 3 | 2009 | 827 | 0.160 |
Why?
|
| Diuresis | 1 | 2019 | 26 | 0.160 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 147 | 0.160 |
Why?
|
| Galectin 3 | 1 | 2019 | 20 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2022 | 183 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 105 | 0.160 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2019 | 5 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 977 | 0.160 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2019 | 64 | 0.150 |
Why?
|
| Preventive Health Services | 1 | 2019 | 39 | 0.150 |
Why?
|
| Recombination, Genetic | 2 | 2001 | 442 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 886 | 0.150 |
Why?
|
| Intraoperative Period | 1 | 2018 | 93 | 0.150 |
Why?
|
| Disease Management | 2 | 2019 | 341 | 0.150 |
Why?
|
| Urination | 1 | 2018 | 40 | 0.150 |
Why?
|
| Urodynamics | 1 | 2019 | 125 | 0.150 |
Why?
|
| Prescription Drugs | 1 | 2019 | 39 | 0.150 |
Why?
|
| Young Adult | 5 | 2019 | 6630 | 0.150 |
Why?
|
| Postoperative Period | 3 | 2014 | 311 | 0.150 |
Why?
|
| Exercise Test | 2 | 2023 | 172 | 0.150 |
Why?
|
| Community Health Services | 1 | 2019 | 81 | 0.140 |
Why?
|
| Hospitals | 1 | 2020 | 312 | 0.140 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 863 | 0.140 |
Why?
|
| Delayed Graft Function | 1 | 2017 | 15 | 0.140 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 760 | 0.140 |
Why?
|
| Neoplasms | 3 | 2018 | 3124 | 0.140 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2016 | 25 | 0.140 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 27 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 411 | 0.130 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 148 | 0.130 |
Why?
|
| Nephrologists | 1 | 2016 | 10 | 0.130 |
Why?
|
| Patients' Rooms | 1 | 2016 | 14 | 0.130 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 82 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2023 | 1186 | 0.120 |
Why?
|
| Cisplatin | 1 | 2018 | 602 | 0.120 |
Why?
|
| Azotemia | 1 | 2015 | 1 | 0.120 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2015 | 4 | 0.120 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2015 | 10 | 0.120 |
Why?
|
| Probability | 1 | 2016 | 357 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 559 | 0.120 |
Why?
|
| Physician's Role | 1 | 2017 | 179 | 0.120 |
Why?
|
| Perioperative Period | 1 | 2015 | 27 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 630 | 0.120 |
Why?
|
| Uromodulin | 1 | 2015 | 15 | 0.120 |
Why?
|
| Containment of Biohazards | 1 | 2015 | 9 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 12 | 0.120 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 1593 | 0.120 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2015 | 32 | 0.120 |
Why?
|
| Forecasting | 1 | 2015 | 311 | 0.110 |
Why?
|
| Tissue Donors | 1 | 2017 | 531 | 0.110 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 72 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2015 | 196 | 0.110 |
Why?
|
| Genome, Human | 1 | 2019 | 803 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 2 | 2025 | 172 | 0.110 |
Why?
|
| Sodium | 1 | 2015 | 335 | 0.110 |
Why?
|
| Contrast Media | 1 | 2018 | 1076 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 404 | 0.110 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2013 | 40 | 0.100 |
Why?
|
| Erythrocyte Transfusion | 1 | 2014 | 69 | 0.100 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 44 | 0.100 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 167 | 0.100 |
Why?
|
| Genomics | 1 | 2009 | 807 | 0.100 |
Why?
|
| Pregnancy | 1 | 2020 | 3112 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2014 | 155 | 0.100 |
Why?
|
| Gastroenterology | 1 | 2015 | 152 | 0.100 |
Why?
|
| Preoperative Care | 2 | 2013 | 405 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2016 | 966 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1480 | 0.100 |
Why?
|
| Logistic Models | 4 | 2017 | 1239 | 0.100 |
Why?
|
| Health Promotion | 1 | 2014 | 168 | 0.100 |
Why?
|
| Global Health | 1 | 2014 | 199 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 864 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2014 | 239 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2793 | 0.090 |
Why?
|
| Debridement | 1 | 2012 | 59 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 55 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 617 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1774 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2014 | 1511 | 0.090 |
Why?
|
| Acute Disease | 2 | 2023 | 855 | 0.090 |
Why?
|
| Drainage | 1 | 2012 | 168 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 555 | 0.090 |
Why?
|
| Ethanol | 3 | 2002 | 262 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2729 | 0.080 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 85 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 391 | 0.080 |
Why?
|
| Hypercapnia | 1 | 2009 | 46 | 0.080 |
Why?
|
| Animals | 7 | 2010 | 28054 | 0.080 |
Why?
|
| Anticoagulants | 3 | 2020 | 448 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 46 | 0.080 |
Why?
|
| Calcium Channel Blockers | 1 | 2009 | 121 | 0.080 |
Why?
|
| Infant | 4 | 2023 | 3207 | 0.080 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 2021 | 9 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 161 | 0.080 |
Why?
|
| Gentamicins | 1 | 2008 | 21 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 379 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2013 | 575 | 0.070 |
Why?
|
| Rhabdomyolysis | 1 | 2008 | 28 | 0.070 |
Why?
|
| Models, Animal | 1 | 2009 | 281 | 0.070 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 369 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 2556 | 0.070 |
Why?
|
| North America | 2 | 2013 | 188 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1117 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2011 | 98 | 0.070 |
Why?
|
| Canada | 2 | 2020 | 205 | 0.070 |
Why?
|
| Elective Surgical Procedures | 1 | 2008 | 155 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 808 | 0.060 |
Why?
|
| Cause of Death | 2 | 2019 | 270 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2008 | 464 | 0.060 |
Why?
|
| Adolescent | 3 | 2013 | 9495 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2025 | 171 | 0.060 |
Why?
|
| Datasets as Topic | 1 | 2024 | 81 | 0.050 |
Why?
|
| Mice, Inbred Strains | 2 | 2002 | 297 | 0.050 |
Why?
|
| Chemokines | 1 | 2023 | 74 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2022 | 7 | 0.050 |
Why?
|
| Microcirculation | 1 | 2023 | 108 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2023 | 168 | 0.050 |
Why?
|
| Causality | 1 | 2022 | 81 | 0.050 |
Why?
|
| Immunoassay | 2 | 2013 | 93 | 0.050 |
Why?
|
| Reagent Strips | 1 | 2011 | 4 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2022 | 37 | 0.050 |
Why?
|
| Immunosenescence | 1 | 2021 | 4 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2021 | 83 | 0.040 |
Why?
|
| Catalepsy | 1 | 2000 | 3 | 0.040 |
Why?
|
| Hematuria | 1 | 2021 | 50 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 68 | 0.040 |
Why?
|
| Lod Score | 1 | 2000 | 153 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2025 | 955 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 148 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 390 | 0.040 |
Why?
|
| Interferon Type I | 1 | 2021 | 195 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 173 | 0.040 |
Why?
|
| Galectins | 1 | 2019 | 11 | 0.040 |
Why?
|
| APACHE | 1 | 2019 | 22 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2011 | 694 | 0.040 |
Why?
|
| Tertiary Prevention | 1 | 2019 | 2 | 0.040 |
Why?
|
| Arousal | 1 | 2000 | 171 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2019 | 149 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 175 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2021 | 433 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2019 | 57 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 2019 | 109 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 205 | 0.040 |
Why?
|
| Professional Role | 1 | 2019 | 41 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1756 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 82 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2002 | 628 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 247 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2019 | 172 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 145 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 163 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 152 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 190 | 0.030 |
Why?
|
| Research | 1 | 2019 | 254 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2021 | 441 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 1194 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2506 | 0.030 |
Why?
|
| Mice, Inbred DBA | 3 | 2002 | 148 | 0.030 |
Why?
|
| Drug Labeling | 1 | 2017 | 40 | 0.030 |
Why?
|
| Internationality | 1 | 2017 | 71 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 224 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 94 | 0.030 |
Why?
|
| Decision Trees | 1 | 2016 | 62 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 120 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2017 | 221 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2015 | 67 | 0.030 |
Why?
|
| Reimbursement Mechanisms | 1 | 2015 | 41 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1024 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2038 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 462 | 0.030 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2015 | 15 | 0.030 |
Why?
|
| Ebolavirus | 1 | 2015 | 7 | 0.030 |
Why?
|
| Patient Isolation | 1 | 2015 | 14 | 0.030 |
Why?
|
| Body Fluids | 1 | 2015 | 34 | 0.030 |
Why?
|
| Developed Countries | 1 | 2015 | 25 | 0.030 |
Why?
|
| Contraindications | 1 | 2015 | 70 | 0.030 |
Why?
|
| Equipment Contamination | 1 | 2015 | 26 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 296 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 763 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 102 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2015 | 53 | 0.030 |
Why?
|
| Mice | 4 | 2002 | 12137 | 0.030 |
Why?
|
| Travel | 1 | 2015 | 72 | 0.030 |
Why?
|
| Mortality | 1 | 2015 | 150 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2015 | 156 | 0.030 |
Why?
|
| Receptors, Angiotensin | 1 | 2013 | 12 | 0.030 |
Why?
|
| Acetylcholinesterase | 1 | 2013 | 48 | 0.030 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2013 | 46 | 0.030 |
Why?
|
| Health Policy | 1 | 2015 | 190 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2015 | 317 | 0.030 |
Why?
|
| Enzyme Assays | 1 | 2013 | 19 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 261 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 276 | 0.020 |
Why?
|
| Equipment Design | 1 | 2013 | 420 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 427 | 0.020 |
Why?
|
| Medicare | 1 | 2015 | 440 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 306 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2011 | 1 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 729 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1926 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 661 | 0.020 |
Why?
|
| Organ Dysfunction Scores | 1 | 2010 | 30 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 902 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 399 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 657 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 2396 | 0.020 |
Why?
|
| Mass Screening | 1 | 2015 | 675 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2002 | 3375 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2002 | 1108 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2002 | 148 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 475 | 0.010 |
Why?
|
| Haloperidol | 1 | 2000 | 29 | 0.010 |
Why?
|
| Dopamine Antagonists | 1 | 2000 | 34 | 0.010 |
Why?
|
| Central Nervous System Depressants | 1 | 2000 | 45 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 1865 | 0.010 |
Why?
|
| Phenotype | 1 | 2001 | 2502 | 0.010 |
Why?
|